Birmingham startup using clinical trials to improve medical care for minorities
BIRMINGHAM, Ala. (WIAT) — Birmingham startup Acclinate is conducting medical trials focused on minorities to better address the medical needs of their communities.
Tiffany Whitlow and Del Smith founded Acclinate in 2020 and now have over 50 employees in a footprint that includes Birmingham, Huntsville, and Washington, D.C.
Time running out to save a slice of civil rights history in the Texas Panhandle
For Whitlow, starting Acclinate was personal.
'My son was diagnosed with asthma,' said Whitlow. 'He was given an albuterol inhaler. I had no idea at the time albuterol is 47% less effective in African-Americans and 67% less effective in Puerto Ricans.'
The 2020 census reported that minorities make up 40% of the U.S. population, but only participate in 2% of clinical trials. Because they are not included in the research, the medication is less effective for some groups.
Skepticism for trials is motivated by events like the Tuskegee Syphilis Study, which studied untreated syphilis in African-American men without their consent, even after treatment became widely available. The study ended in 1972.
Another event motivating skepticism is the harvesting and study of Henrietta Lacks' cervical cells in 1951, which were used without her knowledge or consent.
'You can't just shy over that,' said Whitlow. 'People want to know that you're aware.'
With more than 120,000 people participating in Acclinate's trials, their influence is growing. Whitlow plans to increase that number to 500,000 in the coming months.
For more information, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
12 hours ago
- New York Post
What is Graves' disease? All about ‘The Boys' star Erin Moriarty's diagnosis
Erin Moriarty is getting candid about her health — and urging fans to listen to their bodies. The Boys star, 30, revealed on Instagram Thursday that she was diagnosed with Graves' disease last month after initially chalking up her symptoms to 'stress and fatigue.' 'Within 24 hours of beginning treatment, I felt the light coming back on. It's been increasing ever since,' she wrote. 'If yours is dimming, even slightly, go get checked.' 6 Erin Moriarty was diagnosed with Graves' disease in May. Deadline via Getty Images The autoimmune disorder affects about 1 in 100 Americans and can cause everything from anxiety and weight loss to bulging eyes and heart issues. Here's everything you need to know, including how to spot it and what to do next. What is Graves' disease? It's chronic autoimmune disorder that hijacks your thyroid gland, sending it into overdrive and flooding your body with more hormones than it needs, according to the National Institutes of Health. Thyroid hormones control how your body burns energy, impacting nearly every organ. When there's too much of them, it turbo-charges your metabolism and can trigger a wide range of symptoms. 6 The thyroid is a small, butterfly-shaped gland located in the front of your neck. Science RF – What are the symptoms of Graves' Disease? Early signs often include heat intolerance, increased appetite, difficulty sleeping, fatigue and nervousness, anxiety or irritability, according to the Mayo Clinic. As the disease progresses, you might experience unintentional weight loss, heart palpitations, trembling hands, frequent bowel movements and shortness of breath. Graves' can also disrupt menstrual cycles, cause erectile dysfunction and reduce libido. 6 Moriarty first assumed her symptoms were caused by stress and fatigue. Erin Moriarty / Instagram Around 1 in 3 people with Graves' have eye problems known as Graves' ophthalmopathy, which can cause: Bulging or puffy eyes Blurred or double vision Gritty, irritated eyes Eye pain or pressure Sensitivity to light In rare cases, patients can develop thickened, darkened skin — usually on the shins or tops of the feet — that looks and feels like orange peel. This comes from a buildup of protein in the skin. It's often mild and painless. What causes Graves' disease? Scientists aren't completely sure. Graves' disease strikes when your immune system goes rogue, overproducing an antibody that prompts your thyroid to flood your body with too many hormones, according to the Cleveland Clinic. 6 Excess thyroid hormones can lead to increased heart rate, irregular rhythms and heart failure. JustLife – Experts say genetics play a major role, with one study estimating that genes account for 79% of the risk. The rest likely comes from environmental triggers like stress, hormonal changes or infections. Who's at risk for Graves' disease? Graves' disease is relatively common, affecting about 1% of people in the US. But it disproportionately affects women, who are five times more likely to get it than men, according to Yale Medicine. Your risk increases if you have a family history of Graves' or other autoimmune conditions like vitiligo, type 1 diabetes or rheumatoid arthritis. Low levels of selenium and vitamin D, along with smoking, may also increase your chances. 6 Smoking is a significant risk factor for Graves' disease. Quitting can help improve patient outcomes. Adobe Stock How is Graves' disease treated? In the US, treatment usually starts with medications like methimazole or propylthiouracil, which work to reduce the production of thyroid hormones, according to ColumbiaDoctors. Most patients start feeling better soon after, but it takes 12 to 18 months to see if the disease goes into remission — meaning the thyroid calms down and antibody levels drop. Up to half of patients achieve remission, but it's not a guaranteed cure. Graves' can flare up again later. 6 Graves' disease is often associated with weight loss despite increased appetite. Prostock-studio – 'For some people, Graves' disease has a clear beginning and end. For others, it's a chronic condition that can be controlled but not cured,' said Dr. Hyesoo Lowe, medical director of the Columbia Thyroid Center. If a patient doesn't go into remission, doctors may recommend radioiodine therapy, which gradually destroys overactive thyroid cells, or surgery to remove the gland entirely. While this can cause hypothyroidism, or too little thyroid hormone, replacement pills are available to keep things balanced. What happens if you don't treat Graves' disease? Ignoring the autoimmune disorder can lead to serious complications. It can cause atrial fibrillation, a dangerous irregular heartbeat that increases the risk of heart failure and stroke. It also weakens bones, raising the chance of fractures. There's a higher risk of thyroid cancer, too. In rare cases, untreated Graves' can trigger a life-threatening thyroid storm — a sudden surge of thyroid hormones. Pregnant women with untreated Graves' risk preeclampsia, miscarriage, premature labor and low birth weight for their babies.
Business Upturn
14 hours ago
- Business Upturn
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 (150 mg Q4W) Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1. The data were presented today by Dr. Martin Metz, Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin, in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 (weekly urticaria activity score) compared to placebo across multiple dose groups, including improvements in quality of life and angioedema measurements, and demonstrated a favorable safety profile. The data presented today further support these results by demonstrating improvements in AAS7 (weekly angioedema activity score) and additional measures of angioedema control over the 52 week treatment period. AAS7 measures the frequency and intensity of angioedema episodes, where higher scores indicate increased angioedema activity. 'The majority of patients with severe CSU suffer with angioedema, which is often extremely painful and causes disfigurement, dramatically impacting quality of life,' said Diane C. Young, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. 'Consistent with previously reported clinical outcomes, we observed rapid, profound angioedema relief with barzolvolimab treatment and this benefit continued to improve over 52 weeks of therapy for patients. These data add to the unprecedented 76 week efficacy and safety data we presented yesterday at EAACI and continue to support barzolvolimab's potential to redefine the treatment landscape and meet the goals of CSU therapy—rapid, profound, durable complete response and improved quality of life across a broad patient population.' Summary of Key Findings: Patients on study had severe CSU. Over 70% of patients had a weekly urticaria activity score (UAS7) greater than 28 at baseline and reported very high rates of angioedema at baseline. Barzolvolimab demonstrated rapid, robust and durable improvements in angioedema symptoms over the treatment period. At Week 52, an 86% mean reduction from baseline was reported for 150 mg Q4W arm and an 82% reduction was reported for the 300 mg Q8W. Up to 77% of patients treated with barzolvolimab who had angioedema at baseline were angioedema free (AAS7=0) at Week 52. Patients treated with barzolvolimab were angioedema free up to 72% of the time over the 52 week treatment period. Up to 87% of patients reported clinically meaningful improvement ( > 8 point) in AAS7 at Week 52. 1 DermNet . About Barzolvolimab Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU Study The randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients entered a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 Program Celldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU) CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit Forward Looking Statement This release contains 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'will,' 'may,' 'should,' or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under 'Risk Factors' in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337 [email protected]
Yahoo
16 hours ago
- Yahoo
Highline Lake State Park can't confirm giardia was found in its water
MESA COUNTY, Colo. (KREX) – After social media posts circulated online about the presence of giardia found in Highline Lake, officials responded to the claims. They said although they cannot confirm that giardia was contracted from the lake, they discourage drinking any untreated water, especially from lakes and streams. Giardia is a naturally occurring microorganism, that when swallowed, can cause illness. Officials encourage residents to wash their hands or shower after coming into contact with untreated water. The park tests lake water every week for E. coli, but it does not test for microorganisms, such as giardia, that are typically found in untreated water. All E. coli tests have returned under a threshold of concern, officials said. If a test shows too much E. coli, officials said they would immediately close the swim beach and post park alerts. 'We take the safety of our visitors seriously and encourage anyone who thinks they may be unwell to seek medical attention,' officials said in a statement. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
